News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB Japan Co., Ltd. , Daiichi Pharmaceutical (JPN) To Reinforce Their Collaboration For Antiallergic Agent Zyrtec


10/19/2005 5:09:04 PM

Tokyo (JCN) - UCB Japan (UCBJ) and Daiichi Pharmaceutical have agreed to form a long-term alliance in sales of Zyrtec Tablet 5 and Zyrtec Tablet 10, UCBJ's proprietary antiallergic agent. Under the terms of the agreement, Daiichi Pharmaceutical will retain the right to co-promote the product with Sankyo until September when their joint holding company Daiichi Sankyo is established.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES